RYR2 and neoplasm: Subsequently, the statistics of gene mutations in the TCGA-LUAD showed that 88.95% of tumor samples had gene mutations, including 47% of TP53 mutations, 41% of TTN mutations, 40% of MUC16 mutations, and 34% of RYR2 mutations (Supplementary Figure S1).